HC Wainwright Reiterates Buy Rating for Evotec (NASDAQ:EVO)

HC Wainwright reaffirmed their buy rating on shares of Evotec (NASDAQ:EVO) in a research note published on Thursday,Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock. HC Wainwright also issued estimates for Evotec’s Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at $0.01 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS and FY2025 earnings at $0.02 EPS.

EVO has been the subject of several other reports. Jefferies Financial Group downgraded Evotec from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $8.70 to $3.80 in a report on Monday, October 7th. Deutsche Bank Aktiengesellschaft downgraded Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. Finally, Morgan Stanley cut Evotec from an “overweight” rating to an “equal weight” rating and dropped their target price for the stock from $15.00 to $6.00 in a research report on Monday, July 29th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Evotec has an average rating of “Hold” and an average target price of $5.93.

Evotec Price Performance

NASDAQ EVO traded down $0.12 during trading hours on Thursday, hitting $4.13. The company’s stock had a trading volume of 188,533 shares, compared to its average volume of 116,174. Evotec has a 12 month low of $2.85 and a 12 month high of $12.00. The company’s 50 day simple moving average is $3.51 and its two-hundred day simple moving average is $4.25. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.83 and a quick ratio of 1.73.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in EVO. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Evotec during the 2nd quarter valued at about $87,000. Clear Harbor Asset Management LLC purchased a new position in shares of Evotec during the 3rd quarter valued at about $104,000. Cetera Advisors LLC purchased a new position in shares of Evotec during the 1st quarter valued at about $188,000. Mediolanum International Funds Ltd purchased a new position in shares of Evotec during the 3rd quarter valued at about $512,000. Finally, DCF Advisers LLC lifted its position in shares of Evotec by 140.5% during the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after buying an additional 67,156 shares in the last quarter. 5.81% of the stock is owned by hedge funds and other institutional investors.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.